Trials / Withdrawn
WithdrawnNCT00771043
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON) as measured by RNFL thickness from Optical Coherence Tomography in patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TYSABRI and AVONEX | TYSABRI and AVONEX treatment per package insert. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-08-01
- Completion
- 2010-06-01
- First posted
- 2008-10-10
- Last updated
- 2024-06-03
Source: ClinicalTrials.gov record NCT00771043. Inclusion in this directory is not an endorsement.